STOCK TITAN

[Form 4] Nuvation Bio Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

David Hung, President, CEO, Director, and 10% owner of Nuvation Bio (NUVB), has made a significant insider purchase of 500,000 shares of Class A Common Stock on June 16, 2025. The shares were acquired at a weighted-average price of $1.787 per share, with purchase prices ranging from $1.64 to $1.88.

Following this transaction, Hung's direct ownership increased to 59,281,054 shares. The substantial purchase by the company's chief executive, representing an investment of approximately $893,500, may signal management's confidence in the company's future prospects.

Key transaction details:

  • Transaction type: Direct purchase of common stock
  • Total transaction value: ~$893,500
  • Filing was signed by Stephen Dang as attorney-in-fact
  • No derivative securities were involved in this transaction

David Hung, Presidente, CEO, Direttore e proprietario del 10% di Nuvation Bio (NUVB), ha effettuato un importante acquisto interno di 500.000 azioni di Azioni Ordinarie di Classe A il 16 giugno 2025. Le azioni sono state acquistate a un prezzo medio ponderato di $1,787 per azione, con prezzi di acquisto compresi tra $1,64 e $1,88.

Dopo questa operazione, la proprietà diretta di Hung è salita a 59.281.054 azioni. Questo significativo acquisto da parte dell'amministratore delegato, che rappresenta un investimento di circa $893.500, potrebbe indicare la fiducia della direzione nelle prospettive future dell'azienda.

Dettagli principali della transazione:

  • Tipo di transazione: acquisto diretto di azioni ordinarie
  • Valore totale della transazione: circa $893.500
  • La documentazione è stata firmata da Stephen Dang come procuratore
  • In questa operazione non sono stati coinvolti titoli derivati

David Hung, Presidente, CEO, Director y propietario del 10% de Nuvation Bio (NUVB), realizó una compra interna significativa de 500,000 acciones de acciones comunes Clase A el 16 de junio de 2025. Las acciones se adquirieron a un precio promedio ponderado de $1.787 por acción, con precios de compra que oscilaron entre $1.64 y $1.88.

Tras esta transacción, la propiedad directa de Hung aumentó a 59,281,054 acciones. La considerable compra por parte del director ejecutivo, que representa una inversión de aproximadamente $893,500, podría indicar la confianza de la gerencia en las perspectivas futuras de la empresa.

Detalles clave de la transacción:

  • Tipo de transacción: compra directa de acciones comunes
  • Valor total de la transacción: aproximadamente $893,500
  • El formulario fue firmado por Stephen Dang como apoderado
  • No se involucraron valores derivados en esta transacción

David Hung은 Nuvation Bio(NUVB)의 회장, CEO, 이사이자 10% 지분 보유자로서 2025년 6월 16일에 500,000주의 클래스 A 보통주를 대규모 내부자 매수하였습니다. 주당 가중평균 매입 가격은 $1.787이며, 매입 가격은 $1.64에서 $1.88 사이였습니다.

이번 거래 후 Hung의 직접 소유 주식 수는 59,281,054주로 증가하였습니다. 약 $893,500에 달하는 이번 대규모 매수는 회사 경영진이 회사의 미래 전망에 대해 자신감을 갖고 있음을 시사할 수 있습니다.

주요 거래 내용:

  • 거래 유형: 보통주 직접 매수
  • 총 거래 금액: 약 $893,500
  • 서류는 법정대리인인 Stephen Dang이 서명함
  • 이번 거래에는 파생 증권이 포함되지 않음

David Hung, Président, PDG, Directeur et détenteur de 10% de Nuvation Bio (NUVB), a réalisé un achat important d'initié de 500 000 actions ordinaires de classe A le 16 juin 2025. Les actions ont été acquises à un prix moyen pondéré de 1,787 $ par action, avec des prix d'achat allant de 1,64 $ à 1,88 $.

Suite à cette transaction, la détention directe de Hung est passée à 59 281 054 actions. Cet achat substantiel par le directeur général, représentant un investissement d'environ 893 500 $, pourrait indiquer la confiance de la direction dans les perspectives futures de l'entreprise.

Détails clés de la transaction :

  • Type de transaction : achat direct d'actions ordinaires
  • Valeur totale de la transaction : environ 893 500 $
  • Le dépôt a été signé par Stephen Dang en tant que mandataire
  • Aucun titre dérivé n'a été impliqué dans cette transaction

David Hung, Präsident, CEO, Direktor und 10% Eigentümer von Nuvation Bio (NUVB), hat am 16. Juni 2025 einen bedeutenden Insiderkauf von 500.000 Aktien der Klasse A Stammaktien getätigt. Die Aktien wurden zu einem gewichteten Durchschnittspreis von $1,787 pro Aktie erworben, mit Kaufpreisen zwischen $1,64 und $1,88.

Nach dieser Transaktion erhöhte sich Hungs direkte Beteiligung auf 59.281.054 Aktien. Der erhebliche Kauf durch den Geschäftsführer, der eine Investition von etwa $893.500 darstellt, könnte auf das Vertrauen des Managements in die zukünftigen Aussichten des Unternehmens hinweisen.

Wichtige Transaktionsdetails:

  • Transaktionstyp: Direkter Kauf von Stammaktien
  • Gesamtwert der Transaktion: ca. $893.500
  • Die Einreichung wurde von Stephen Dang als Bevollmächtigter unterzeichnet
  • Keine derivativen Wertpapiere waren an dieser Transaktion beteiligt
Positive
  • CEO David Hung purchased 500,000 shares at ~$1.79 per share, representing a significant $893,500 open market purchase showing strong insider confidence
  • The CEO maintains a substantial position of over 59.2 million shares, demonstrating long-term commitment to the company
Negative
  • None.

David Hung, Presidente, CEO, Direttore e proprietario del 10% di Nuvation Bio (NUVB), ha effettuato un importante acquisto interno di 500.000 azioni di Azioni Ordinarie di Classe A il 16 giugno 2025. Le azioni sono state acquistate a un prezzo medio ponderato di $1,787 per azione, con prezzi di acquisto compresi tra $1,64 e $1,88.

Dopo questa operazione, la proprietà diretta di Hung è salita a 59.281.054 azioni. Questo significativo acquisto da parte dell'amministratore delegato, che rappresenta un investimento di circa $893.500, potrebbe indicare la fiducia della direzione nelle prospettive future dell'azienda.

Dettagli principali della transazione:

  • Tipo di transazione: acquisto diretto di azioni ordinarie
  • Valore totale della transazione: circa $893.500
  • La documentazione è stata firmata da Stephen Dang come procuratore
  • In questa operazione non sono stati coinvolti titoli derivati

David Hung, Presidente, CEO, Director y propietario del 10% de Nuvation Bio (NUVB), realizó una compra interna significativa de 500,000 acciones de acciones comunes Clase A el 16 de junio de 2025. Las acciones se adquirieron a un precio promedio ponderado de $1.787 por acción, con precios de compra que oscilaron entre $1.64 y $1.88.

Tras esta transacción, la propiedad directa de Hung aumentó a 59,281,054 acciones. La considerable compra por parte del director ejecutivo, que representa una inversión de aproximadamente $893,500, podría indicar la confianza de la gerencia en las perspectivas futuras de la empresa.

Detalles clave de la transacción:

  • Tipo de transacción: compra directa de acciones comunes
  • Valor total de la transacción: aproximadamente $893,500
  • El formulario fue firmado por Stephen Dang como apoderado
  • No se involucraron valores derivados en esta transacción

David Hung은 Nuvation Bio(NUVB)의 회장, CEO, 이사이자 10% 지분 보유자로서 2025년 6월 16일에 500,000주의 클래스 A 보통주를 대규모 내부자 매수하였습니다. 주당 가중평균 매입 가격은 $1.787이며, 매입 가격은 $1.64에서 $1.88 사이였습니다.

이번 거래 후 Hung의 직접 소유 주식 수는 59,281,054주로 증가하였습니다. 약 $893,500에 달하는 이번 대규모 매수는 회사 경영진이 회사의 미래 전망에 대해 자신감을 갖고 있음을 시사할 수 있습니다.

주요 거래 내용:

  • 거래 유형: 보통주 직접 매수
  • 총 거래 금액: 약 $893,500
  • 서류는 법정대리인인 Stephen Dang이 서명함
  • 이번 거래에는 파생 증권이 포함되지 않음

David Hung, Président, PDG, Directeur et détenteur de 10% de Nuvation Bio (NUVB), a réalisé un achat important d'initié de 500 000 actions ordinaires de classe A le 16 juin 2025. Les actions ont été acquises à un prix moyen pondéré de 1,787 $ par action, avec des prix d'achat allant de 1,64 $ à 1,88 $.

Suite à cette transaction, la détention directe de Hung est passée à 59 281 054 actions. Cet achat substantiel par le directeur général, représentant un investissement d'environ 893 500 $, pourrait indiquer la confiance de la direction dans les perspectives futures de l'entreprise.

Détails clés de la transaction :

  • Type de transaction : achat direct d'actions ordinaires
  • Valeur totale de la transaction : environ 893 500 $
  • Le dépôt a été signé par Stephen Dang en tant que mandataire
  • Aucun titre dérivé n'a été impliqué dans cette transaction

David Hung, Präsident, CEO, Direktor und 10% Eigentümer von Nuvation Bio (NUVB), hat am 16. Juni 2025 einen bedeutenden Insiderkauf von 500.000 Aktien der Klasse A Stammaktien getätigt. Die Aktien wurden zu einem gewichteten Durchschnittspreis von $1,787 pro Aktie erworben, mit Kaufpreisen zwischen $1,64 und $1,88.

Nach dieser Transaktion erhöhte sich Hungs direkte Beteiligung auf 59.281.054 Aktien. Der erhebliche Kauf durch den Geschäftsführer, der eine Investition von etwa $893.500 darstellt, könnte auf das Vertrauen des Managements in die zukünftigen Aussichten des Unternehmens hinweisen.

Wichtige Transaktionsdetails:

  • Transaktionstyp: Direkter Kauf von Stammaktien
  • Gesamtwert der Transaktion: ca. $893.500
  • Die Einreichung wurde von Stephen Dang als Bevollmächtigter unterzeichnet
  • Keine derivativen Wertpapiere waren an dieser Transaktion beteiligt
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hung David

(Last) (First) (Middle)
C/O NUVATION BIO INC.
1500 BROADWAY, SUITE 1401

(Street)
NEW YORK NY 10036

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/16/2025 P 500,000 A $1.787(1) 59,281,054 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. ) The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.64 to $1.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
/s/ Stephen Dang, Attorney-in-Fact 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of NUVB stock did CEO David Hung purchase on June 16, 2025?

According to the Form 4 filing, CEO David Hung purchased 500,000 shares of NUVB Class A Common Stock on June 16, 2025.

What was the purchase price for NUVB shares in CEO David Hung's recent insider transaction?

The shares were purchased at a weighted-average price of $1.787 per share, with the actual purchase prices ranging from $1.64 to $1.88 per share.

How many NUVB shares does David Hung own after his June 2025 purchase?

Following the reported transaction, David Hung directly owns 59,281,054 shares of Nuvation Bio Inc. (NUVB) Class A Common Stock.

What positions does David Hung hold at NUVB according to the Form 4?

According to the Form 4, David Hung serves as President and CEO of Nuvation Bio Inc. He is also a Director and a 10% Owner of the company.

When was NUVB's Form 4 insider trading report filed with the SEC?

The Form 4 was filed with the SEC on June 28, 2025, reporting a transaction that occurred on June 16, 2025. The form was signed by Stephen Dang as Attorney-in-Fact on June 18, 2025.
Nuvation Bio Inc

NYSE:NUVB

NUVB Rankings

NUVB Latest News

NUVB Latest SEC Filings

NUVB Stock Data

690.73M
274.53M
26.68%
58.95%
7.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO